Vertex Pharmaceuticals Inc

Healthcare · Biotechnology

516.30$ +0.6% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Balance Sheet

Vertex Pharmaceuticals Inc (VRTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 26,143 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet VRTX
Line item	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Assets	144	296	266	232	773	925	816	724	545	549	922	601	980	1,955	1,725	2,204	2,759	2,319	2,336	2,497	2,894	3,546	6,246	8,318	11,752	13,433	18,151	22,730	22,533	26,143
Current Assets	132	282	249	195	503	776	657	594	401	385	771	497	868	1,307	1,057	1,331	1,590	1,589	1,547	1,355	1,761	2,483	3,702	4,823	8,133	9,561	13,235	14,144	9,596	11,201
Cash	35	72	24	32	322	189	108	98	55	78	213	356	389	447	243	475	489	569	625	715	1,184	1,665	2,650	3,109	5,988	6,795	10,504	10,369	4,570	5,088
Cash & Short-Term Investments	35	72	24	188	460	743	635	583	386	361	705	461	832	1,285	1,031	969	1,321	1,465	1,387	1,042	1,435	2,089	3,168	3,808	6,659	7,525	10,779	11,218	6,116	6,611
Receivables	–	–	–	6.0	34	20	13	7.3	12	21	63	31	23	9.6	13	183	143	86	90	178	201	281	410	634	885	1,137	1,442	1,563	1,609	2,053
Inventory	–	–	–	–	–	6.6	4.3	–	–	–	–	–	–	0.0	0.0	112	30	14	31	56	78	112	124	168	281	353	461	739	1,205	1,687
Property, Plant & Equipment	–	–	–	–	28	80	96	80	64	55	62	67	68	62	72	133	434	697	716	698	698	789	812	833	959	1,094	1,456	–	–	–
Goodwill	–	–	–	–	–	–	–	–	–	–	–	–	–	26	26	31	31	31	40	50	50	50	50	1,002	1,002	1,002	1,088	1,088	1,088	1,088
Intangible Assets	–	–	–	–	–	–	–	–	–	–	–	–	–	519	519	664	664	106	29	284	284	29	50	400	400	400	604	840	826	424
Total Liabilities	13	20	20	23	427	450	437	532	510	310	416	330	742	859	1,221	1,239	1,525	963	1,238	1,404	1,556	1,504	1,811	2,233	3,065	3,333	4,238	5,150	6,124	7,477
Current Liabilities	7.1	14	13	19	70	92	65	139	154	100	251	199	217	285	475	839	433	398	368	506	8.0	807	715	1,335	1,878	2,142	2,742	3,547	3,565	3,861
Short-Term Debt	2.9	2.5	2.8	2.4	-26	4.6	2.2	4.7	95	60	104	20	106	64	137	195	14	17	32	87	319	23	9.8	39	42	80	89	84	92	83
Accounts Payable	1.4	4.2	2.8	14	8.4	12	17	12	6.7	6.2	15	33	52	37	36	75	101	49	71	75	61	74	111	88	155	195	304	365	413	462
Long-Term Debt	–	–	–	–	347	323	326	333	335	180	20	–	288	122	400	456	668	441	754	697	486	563	562	–	–	–	–	–	–	–
Shareholders' Equity	131	276	246	209	514	475	379	193	35	239	506	271	239	1,096	504	966	1,234	1,356	1,075	1,093	1,338	2,042	4,435	6,085	8,687	10,100	13,913	17,580	16,410	18,666
Retained Earnings	-97	-117	-150	-191	-230	-315	-423	-620	-786	-990	-1,196	-1,588	-2,048	-2,690	-3,444	-3,415	-3,522	-3,967	-4,705	-5,262	-5,374	-5,120	-2,989	-1,853	859	3,201	6,523	10,142	9,607	13,560
Shares Outstanding	37	49	51	51	68	74	76	77	79	89	113	129	141	173	200	209	212	225	235	241	245	253	259	261	263	260	259	261	258	258

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings